Abstract
The gonadal steroid 17β-estradiol (E2) has shown powerful cytoprotective effect on cells. In addition to classical genomic mechanisms of action, E2 also exerts non-classical effects on intracellular signal transduction. Extensive studies during the past two decades have provided evidence that the E2-induced non-classical signaling on second messenger molecules plays a critical role in the neuroprotective effect of E2. These observations provide a unique basis for developing non-classical estrogen-like signaling activators that may have potential for clinical use in neuroprotection. In spite of the extensive research over the past decade reviewed here, we are just starting to appreciate the importance and potential of these compounds. Hence, we first describe the molecular characteristics and effects of these activators. Second, we survey recent data as to possible mechanisms underlying the ameliorative actions of selective non-classical estrogen-like signaling activation. In addition, the pitfalls and future aspects of “non-classical”-line activators and its clinical relevance will also be discussed.
Keywords: Estradiol, non-classical estrogen-like signaling activators, ANGELS, estren, compound A, compound B, neuroprotection.
CNS & Neurological Disorders - Drug Targets
Title:Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
Volume: 12 Issue: 8
Author(s): Andrea Kwakowsky, Zsombor Koszegi, Rachel Y. Cheong and Istvan M. Abraham
Affiliation:
Keywords: Estradiol, non-classical estrogen-like signaling activators, ANGELS, estren, compound A, compound B, neuroprotection.
Abstract: The gonadal steroid 17β-estradiol (E2) has shown powerful cytoprotective effect on cells. In addition to classical genomic mechanisms of action, E2 also exerts non-classical effects on intracellular signal transduction. Extensive studies during the past two decades have provided evidence that the E2-induced non-classical signaling on second messenger molecules plays a critical role in the neuroprotective effect of E2. These observations provide a unique basis for developing non-classical estrogen-like signaling activators that may have potential for clinical use in neuroprotection. In spite of the extensive research over the past decade reviewed here, we are just starting to appreciate the importance and potential of these compounds. Hence, we first describe the molecular characteristics and effects of these activators. Second, we survey recent data as to possible mechanisms underlying the ameliorative actions of selective non-classical estrogen-like signaling activation. In addition, the pitfalls and future aspects of “non-classical”-line activators and its clinical relevance will also be discussed.
Export Options
About this article
Cite this article as:
Kwakowsky Andrea, Koszegi Zsombor, Cheong Y. Rachel and Abraham M. Istvan, Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications, CNS & Neurological Disorders - Drug Targets 2013; 12 (8) . https://dx.doi.org/10.2174/187152731131200123
DOI https://dx.doi.org/10.2174/187152731131200123 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Calcium-suppressed Technique in Dual-layer Detector Computed Tomography to Evaluate Knee Articular Cartilage
Current Medical Imaging A SAR Study: Evaluation of Bromo Derivatives of 8-Substituted Quinolines as Novel Anticancer Agents
Letters in Drug Design & Discovery Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Targeting Protein Degradation in the Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents
Recent Patents on Anti-Cancer Drug Discovery 1'-methylspiro[indoline-3,4'-piperidine] Derivatives: Design, Synthesis, Molecular Docking and Anti-tumor Activity Studies
Letters in Drug Design & Discovery Melanoma: The Radiotherapeutic Point of View; Review of the Current Literature
Reviews on Recent Clinical Trials Identification of Leads from Marine Seaweeds against Human β-tubulin
Letters in Drug Design & Discovery Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
Current Molecular Pharmacology What they are, How they Work and Why they do What they do? The Story of SV40-derived Gene Therapy Vectors and What They Have to Offer
Current Gene Therapy N-Hydroxyurea and Acyl Nitroso Compounds as Nitroxyl (HNO) and Nitric Oxide (NO) Donors
Current Topics in Medicinal Chemistry Cellular Targets and Mechanisms in the Cytotoxic Action of Non-biodegradable Engineered Nanoparticles
Current Drug Metabolism Bioactivity of Chitosan and Its Derivatives
Current Organic Chemistry An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) Nanomedicine based on Nucleic Acids: Pharmacokinetic and Pharmacodynamic Perspectives
Current Pharmaceutical Biotechnology Template Dependent Human DNA Polymerases
Current Topics in Medicinal Chemistry Novel PARP Inhibitor DDPF-20 Induces DNA Damage and Inhibits Angiogenesis through the PI3K/Akt/VEGF Pathway
Anti-Cancer Agents in Medicinal Chemistry Arsenic-exposed Keratinocytes Exhibit Differential microRNAs Expression Profile; Potential Implication of miR-21, miR-200a and miR-141 in Melanoma Pathway
Clinical Cancer Drugs Overview of Naphthalimide Analogs as Anticancer Agents
Current Medicinal Chemistry Cell Arrest and Apoptosis Induced by the Next Generation of Vanadium Based Drugs: Action Mechanism to Structure Relation and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry